Stronger Together: Leveraging Evidence-Based Patient Collaboration and Treatment Strategies to Streamline Success in Multiple Sclerosis

Program Description

With the variety of possible risk factors, presentations, impacts, and preferences among individual patients with multiple sclerosis (MS), it has been well-established that every case of MS is unique. It is perhaps because of this that a collaborative, shared decision-making (SDM) approach has emerged as the preferred model of clinical care. However, in an age of over 20 FDA-approved disease modifying therapies (DMTs) and continuously evolving strategies for monitoring therapeutic response, the scope of shared clinical decisions is increasingly broad. Yet, recent studies suggest that this strategy may not yet have taken hold in the routine care of many patients with MS. As such, this activity includes video-recorded stories from real patients referred by the Multiple Sclerosis Foundation to help highlight the importance of SDM alongside key faculty strategies to enhance its application and maximize each therapeutic decision over the course of MS.

Target Audience

This activity is intended for general neurologists, neurodegenerative disease specialists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Assess evidence-based strategies for patient communication and collaboration to optimize the impact of early management decisions in MS
  • Evaluate evidence-based approaches to early therapy selection and initiation of DMTs based on patient preferences (e.g., modality) and risk factors (e.g., race/ethnicity) to maximize outcomes across diverse populations
  • Align individual patient plans (e.g., pregnancy, change in environment) and characteristics (e.g., age, geographic location) to DMT features to encourage medication adherence and treatment success
  • Employ evidence- and guideline-based recommendations to identify patient personal (e.g., side effects) or clinical (e.g., cognitive impairment, depression) factors that may prompt a therapeutic switch
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

   Scott Newsome, DO, MSCS, FAAN, FANA (Chair)
   Director, Neurosciences Consultation and Infusion Center Stiff Person Syndrome Center
   Johns Hopkins Neuroimmunology and Neurological Infectious Disease Fellowship
   Co-Director, Multiple Sclerosis Experimental Therapeutics Program
   Associate Professor of Neurology
   Baltimore, MD



   Sarah A. Morrow, MD, MS, FRCPC, FAAN
   Director | Multiple Sclerosis Program
   Professor of Neurology | Department of Clinical Neurosciences
   Hotchkiss Brain Institute
   University of Calgary
   Alberta, Canada

   Anne H. Cross, MD  
   Manny and Rosalyn Rosenthal - Dr. John Trotter MS Center Chair in Neuroimmunology
   Professor of Neurology
   Washington University School of Medicine
   St. Louis, MO

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Efficient LLC and was developed in partnership with the Multiple Sclerosis Foundation.


Joint Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

PACE designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

Faculty and Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Newsome reported the following financial relationships:
Grants/Research Support: Biogen, Department of Defense, Genentech, National Multiple Sclerosis Society, Patient Centered Outcomes Research Institute, Roche, The Stiff Person Syndrome Research Foundation
Consulting Fees: Autobahn, Biogen, Bristol Myers Squibb (BMS), EMD Serono, Genentech, Greenwich Biosciences, Horizon Therapeutics, Janssen, Novartis, Roche, Sanofi, TG Therapeutics
Dr. Morrow reported the following financial relationships:
Consulting Fees: Biogen, Celgene, EMD Serono, Novartis, Roche, Sanofi Genzyme, Teva Neurosciences
Grant/Research Support: AbbVie, Biogen, Celgene, EMD Serono, Novartis, Roche, Sanofi
Dr. Cross reported the following financial relationships:
Consulting Fees: Biogen, BMS, EMD Serono, Genentech, Horizon, Janssen, Novartis, Octave, TG Therapeutics
Independent Contractor: EMD Serono, Genentech

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by an educational grant from Mylan Specialty L.P., a Viatris Company.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance


Please login or register to take this course.